CEFAZOLIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Cefazolin Sodium patents expire, and what generic alternatives are available?
Cefazolin Sodium is a drug marketed by Abraxis Pharm, Acs Dobfar, Aurobindo Pharma, Bedford, Cephazone Pharma, Dr Reddys, Facta Farma, Fresenius Kabi Usa, Glaxosmithkline, Hikma, Hikma Farmaceutica, Hospira, Hospira Inc, Qilu, Samson Medcl, Sandoz, Steri Pharma, Teva Pharms, and Hq Spclt Pharma. and is included in thirty-four NDAs.
The generic ingredient in CEFAZOLIN SODIUM is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefazolin Sodium
A generic version of CEFAZOLIN SODIUM was approved as cefazolin sodium by SANDOZ on December 9th, 1988.
Summary for CEFAZOLIN SODIUM
US Patents: | 0 |
Applicants: | 19 |
NDAs: | 34 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 64 |
Clinical Trials: | 8 |
Patent Applications: | 3,003 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in CEFAZOLIN SODIUM? | CEFAZOLIN SODIUM excipients list |
DailyMed Link: | CEFAZOLIN SODIUM at DailyMed |
Recent Clinical Trials for CEFAZOLIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
HK Surgical, Inc. | Phase 2/Phase 3 |
University of California, Riverside | Phase 2/Phase 3 |
University of British Columbia | Early Phase 1 |
Pharmacology for CEFAZOLIN SODIUM
Drug Class | Cephalosporin Antibacterial |